Gyre Therapeutics, Inc. Income Tax Expense
Gyre Therapeutics, Inc. (GYRE) reported Income Tax Expense of -$164.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-08-07
- Gyre Therapeutics, Inc. income tax expense (benefit) for the quarter ending 2026-06-30 was -$164.00K, a 124.77% decline year-over-year.
- Gyre Therapeutics, Inc. income tax expense (benefit) for the quarter ending 2026-03-31 was $621.00K, a 31.08% decline year-over-year.
- Gyre Therapeutics, Inc. income tax expense (benefit) for the quarter ending 2025-12-31 was $1.30M, a 540.39% increase year-over-year.
- Gyre Therapeutics, Inc. income tax expense (benefit) for the quarter ending 2025-09-30 was $1.69M, a 57.64% increase year-over-year.
- Gyre Therapeutics, Inc. income tax expense (benefit) for fiscal 2025 was $4.56M, a 14.36% decline from fiscal 2024.
- Gyre Therapeutics, Inc. income tax expense (benefit) for fiscal 2024 was $5.32M, a 37.52% decline from fiscal 2023.
- Gyre Therapeutics, Inc. income tax expense (benefit) for fiscal 2023 was $8.52M, a 67.03% increase from fiscal 2022.
- Gyre Therapeutics, Inc. income tax expense (benefit) for fiscal 2022 was $5.10M.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 3 month as first filed | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 6 month as first filed | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 9 month as first filed | Income Tax Expense (Benefit) 12 month | Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$164.00K 10-Q · filed 2026-08-07 | $385.00K 10-Q · filed 2026-08-07 | $1.76M derived: sum of 3 quarters · filed 2026-08-07 | $3.45M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2026-03-31 | $621.00K 10-Q · filed 2026-05-08 | $1.92M derived: sum of 2 quarters · filed 2026-05-08 | $3.61M derived: sum of 3 quarters · filed 2026-05-08 | $4.28M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $2.99M derived: sum of 2 quarters · filed 2026-03-13 | $3.65M derived: sum of 3 quarters · filed 2026-08-07 | $4.56M 10-K · filed 2026-03-13 | ||||
| 2025-09-30 | $1.69M 10-Q · filed 2025-11-07 | $2.35M derived: sum of 2 quarters · filed 2026-08-07 | $3.26M 10-Q · filed 2025-11-07 | $3.46M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-06-30 | $662.00K 10-Q · filed 2026-08-07 | $1.56M 10-Q · filed 2026-08-07 | $1.77M derived: sum of 3 quarters · filed 2026-08-07 | $2.84M derived: sum of 4 quarters · filed 2026-08-07 | ||||
| 2025-03-31 | $901.00K 10-Q · filed 2026-05-08 | $1.10M derived: sum of 2 quarters · filed 2026-05-08 | $2.18M derived: sum of 3 quarters · filed 2026-05-08 | $3.67M derived: sum of 4 quarters · filed 2026-05-08 | ||||
| 2024-12-31 | $203.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $1.28M derived: sum of 2 quarters · filed 2026-03-13 | $2.77M derived: sum of 3 quarters · filed 2026-03-13 | $5.32M 10-K · filed 2026-03-13 | ||||
| 2024-09-30 | $1.07M 10-Q · filed 2025-11-07 | $2.57M derived: sum of 2 quarters · filed 2025-11-07 | $5.12M 10-Q · filed 2025-11-07 | $5.82M derived: sum of 4 quarters · filed 2025-11-07 | ||||
| 2024-06-30 | $1.50M 10-Q · filed 2025-08-11 | $4.04M 10-Q · filed 2025-08-11 | $4.74M derived: sum of 3 quarters · filed 2025-08-11 | $8.42M derived: sum of 4 quarters · filed 2025-08-11 | ||||
| 2024-03-31 | $2.55M 10-Q · filed 2025-05-09 | $3.25M derived: sum of 2 quarters · filed 2025-05-09 | $6.92M derived: sum of 3 quarters · filed 2025-05-09 | $9.01M derived: sum of 4 quarters · filed 2025-05-09 | ||||
| 2023-12-31 | $699.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $4.38M derived: sum of 2 quarters · filed 2025-03-17 | $6.46M derived: sum of 3 quarters · filed 2025-03-17 | $8.52M 10-K · filed 2025-03-17 | ||||
| 2023-09-30 | $3.68M 10-Q · filed 2024-11-13 | $0.00 10-Q · filed 2023-10-26 | $5.76M derived: sum of 2 quarters · filed 2024-11-13 | $7.82M 10-Q · filed 2024-11-13 | $16.00K 10-Q · filed 2023-10-26 | $12.91M derived: sum of 4 quarters · filed 2024-11-13 | ||
| 2023-06-30 | $2.08M 10-Q · filed 2024-08-13 | $2.00K 10-Q · filed 2023-08-14 | $4.14M 10-Q · filed 2024-08-13 | $16.00K 10-Q · filed 2023-08-14 | $9.24M derived: sum of 3 quarters · filed 2024-08-13 | $9.24M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $2.05M 10-Q · filed 2024-05-13 | $14.00K 10-Q · filed 2023-05-15 | $7.15M derived: sum of 2 quarters · filed 2024-05-13 | $7.15M derived: sum of 3 quarters · filed 2024-05-13 | $7.15M derived: sum of 4 quarters · filed 2024-05-13 | |||
| 2022-12-31 | $5.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | $5.10M derived: sum of 2 quarters · filed 2024-03-27 | $5.10M derived: sum of 3 quarters · filed 2024-03-27 | $5.10M 10-K · filed 2024-03-27 | $348.00K 10-K · filed 2023-03-30 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-10-26 | $0.00 derived: sum of 2 quarters · filed 2023-10-26 | $0.00 10-Q · filed 2023-10-26 | |||||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | ||||||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | |||||||
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | $21.00K 10-Q · filed 2015-07-31 | $37.00K derived: sum of 3 quarters · filed 2015-07-31 | $48.00K derived: sum of 4 quarters · filed 2015-07-31 | ||||
| 2015-03-31 | $21.00K 10-Q · filed 2015-05-07 | $37.00K derived: sum of 2 quarters · filed 2015-05-07 | $48.00K derived: sum of 3 quarters · filed 2015-05-07 | $93.00K derived: sum of 4 quarters · filed 2015-07-31 | ||||
| 2014-12-31 | $16.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $27.00K derived: sum of 2 quarters · filed 2015-03-16 | $72.00K derived: sum of 3 quarters · filed 2015-07-31 | $3.48M 10-K · filed 2015-03-16 | ||||
| 2014-09-30 | $11.00K 10-Q · filed 2014-11-06 | $56.00K derived: sum of 2 quarters · filed 2015-07-31 | $3.47M 10-Q · filed 2014-11-06 | |||||
| 2014-06-30 | $45.00K 10-Q · filed 2015-07-31 | $3.46M 10-Q · filed 2015-07-31 | ||||||
| 2014-03-31 | $3.41M 10-Q · filed 2015-05-07 | |||||||
| 2013-12-31 | $7.00K 10-K · filed 2015-03-16 | |||||||
| 2012-12-31 | -$101.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | -$101.00K derived: sum of 2 quarters · filed 2015-03-16 | -$101.00K derived: sum of 3 quarters · filed 2015-03-16 | -$101.00K 10-K · filed 2015-03-16 | ||||
| 2012-09-30 | $0.00 10-Q · filed 2012-11-08 | $0.00 derived: sum of 2 quarters · filed 2012-11-08 | $0.00 10-Q · filed 2012-11-08 | |||||
| 2012-06-30 | $0.00 10-Q · filed 2012-08-09 | $0.00 10-Q · filed 2012-08-09 | ||||||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | $0.00 derived: sum of 2 quarters · filed 2014-03-14 | $0.00 derived: sum of 3 quarters · filed 2014-03-14 | $0.00 10-K · filed 2014-03-14 | ||||
| 2011-09-30 | $0.00 10-Q · filed 2012-11-08 | $0.00 derived: sum of 2 quarters · filed 2012-11-08 | $0.00 10-Q · filed 2012-11-08 | |||||
| 2011-06-30 | $0.00 10-Q · filed 2012-08-09 | $0.00 10-Q · filed 2012-08-09 | ||||||
| 2010-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $1.39M derived: sum of 2 quarters · filed 2013-03-15 | $2.90M derived: sum of 3 quarters · filed 2013-03-15 | $3.53M 10-K · filed 2013-03-15 | ||||
| 2010-09-30 | $257.00K 10-Q · filed 2011-11-03 | $1.77M derived: sum of 2 quarters · filed 2011-11-03 | $2.40M 10-Q · filed 2011-11-03 | |||||
| 2010-06-30 | $1.51M 10-Q · filed 2011-08-09 | $2.14M 10-Q · filed 2011-08-09 | ||||||
| 2009-12-31 | -$88.00K 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |